Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: Empagliflozin;   Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors Sponsor:   Boehringer Ingelheim Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials